Loading patent…
AssigneeZymoGenetics, Inc.
InventorsCameron S. BRANDT, Jacob J. Kennedy, Wenfeng Xu, Eugene C. YI, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
Estimating the term…
Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
1-9. (canceled)
An isolated polynucleotide comprising a polynucleotide segment encoding a polypeptide segment that has at least 90% sequence identity with the amino acid sequence set forth in residues 25-266 of SEQ ID NO:2, wherein said polypeptide is capable of specifically binding to human NKp30.
An isolated antibody that specifically binds to a polypeptide segment having the amino acid sequence set forth in residues 25-266 of SEQ ID NO:2.
(canceled)
A method for enhancing human natural killer (NK) cell activity, the method comprising:
A method for decreasing human natural killer (NK) cell activity against a cell expressing zB7H6, the method comprising:
A method for treating bone marrow cell (BMC) allograft rejection in a subject, the method comprising:
(canceled)
A method of screening for an agonist or antagonist of the interaction of zB7H6 with NKp30 comprising:
31-47. (canceled)
A method for depleting or inhibiting the growth of zB7H6-expressing cells comprising contacting said zB7H6-expressing cells with an effective amount of an antibody that specifically binds to a polypeptide segment having the amino acid sequence set forth in residues 25-266 of SEQ ID NO:2 conjugated to a cytotoxic agent.
A method for treating a zB7H6-expressing cancer in a subject comprising administering to the subject an effective amount of that specifically binds to a polypeptide segment having the amino acid sequence set forth in residues 25-266 of SEQ ID NO:2, wherein the antibody:
51-52. (canceled)
(canceled)
57-74. (canceled)
Dependencies are inferred from the claim text.